Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXAGON in Persistent Corneal Epithelial Defects
NCT05966493Phase 2Recruiting
- Sponsor
- Glaukos Corporation
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of lufepirsen in persistent corneal epithelial defect (PED) (3 arms), sponsored by Glaukos Corporation. Primary endpoint: Corneal Re-epithelialization Including Durability. Started Aug 2023; status: recruiting.
02
Drugs
lufepirsen
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT05966493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966493.